Clinical Trials Logo

Clinical Trial Summary

The trial investigates the efficacy of adjuvanted seasonal influenza including H1N1 Fluad (R) in immunocompromised adults who have undergone solid organ or bone marrow transplantation. It is expected that when administered once the vaccine fulfills all serological efficacy criteria required for the elderly population age 60 years and older.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01258023
Study type Interventional
Source HepNet Study House, German Liverfoundation
Contact
Status Completed
Phase Phase 2
Start date November 2010
Completion date April 2012

See also
  Status Clinical Trial Phase
Terminated NCT05074433 - A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults Phase 3
Recruiting NCT03808922 - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study Phase 3
Completed NCT03262584 - Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Recruiting NCT01301755 - Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration N/A
Recruiting NCT03425526 - Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease Phase 1
Terminated NCT02057289 - A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis Phase 1
Active, not recruiting NCT03168815 - Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy N/A
Terminated NCT01069601 - H1N1sw Vaccine in Adult Transplant Recipients Phase 2
Withdrawn NCT05545319 - A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 Phase 2
Completed NCT05020145 - COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States